MTEM Overview

Management Changes: Calidi Biotherapeutics has strengthened its leadership team by appointing Eric Poma, PhD, as CEO and Guy Travis Clifton, MD, as Chief Medical Officer, both bringing extensive biopharmaceutical experience to the company.

Clinical Developments: The FDA has cleared Calidi's IND application for CLD-201, an innovative stem cell-based immunotherapy targeting solid tumors, while the company is advancing its Redtail platform with IL15-superagonist as a key payload for tumor treatment.

Leadership Transition: Calidi Biotherapeutics has appointed Eric Poma, Ph.D., as the new CEO, succeeding Allan Camaisa, who will remain on the Board of Directors. Dr. Poma brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology.

Company Focus: Calidi is advancing its systemic enveloped virotherapy platform and preparing for clinical trials of its therapeutic candidates, aiming to enhance cancer treatment efficacy and patient safety through innovative technologies.

Molecular Templates Inc Delisting Notice: The company received a delisting notice from Nasdaq due to its classification as a "public shell" and failure to meet listing requirements, including not filing its quarterly report and maintaining a minimum stock price.

Stock Trading Impact: Following the announcement, shares of Molecular Templates fell by 60% to 13 cents, with trading set to be suspended on December 26, and the company does not plan to appeal the decision.

FedEx Corporation Performance: FedEx shares surged 8.7% in pre-market trading after reporting stronger-than-expected second-quarter results and announcing plans for a full separation of FedEx Freight into a new publicly traded company.

Stock Movements: Several stocks experienced significant pre-market movements, with Aptose Biosciences gaining 80.5% and Molecular Templates tumbling 49.5% following various company announcements and market reactions.

DocuSign Financial Results: DocuSign, Inc. shares surged 14.1% in pre-market trading after reporting third-quarter revenue of $754.8 million and adjusted earnings of 90 cents per share, both exceeding analyst expectations.

Pre-Market Stock Movements: Various stocks experienced significant fluctuations in pre-market trading, with Universe Pharmaceuticals gaining 196.2% and Oriental Rise Holdings dropping 81.2%, highlighting a volatile market environment.

Spirit Airlines Stock Surge: Spirit Airlines shares increased by 43.5% in pre-market trading after extending the deadline for its 2025 notes, with the stock reaching $2.11.

Other Notable Stock Movements: Several stocks experienced significant changes in pre-market trading, including GRI Bio rising 151.2% and BioVie gaining 98.7%, while some stocks like 1847 Holdings saw a decline of 24.7%.